Categories: News

STARMED Unveils New Brand Identity to Drive Global Multi-Modality Strategy

SEOUL, South Korea, Jan. 8, 2026 /PRNewswire/ — STARMED, a pioneer in innovative minimally invasive treatment solutions, has announced a comprehensive rebranding. Now in its seventeenth year of operation, the company is formally transitioning from a Radiofrequency Ablation (RFA) specialist into a global multi-modality medical technology platform.

- Advertisement -

Established in 2009, STARMED pioneered the first thyroid-dedicated RFA electrode, effectively creating a clinical field that did not previously exist. This technology has since been adopted into various international clinical guidelines and continues to maintain the leading global market share today. Building on this heritage, STARMED has expanded its portfolio to address diverse clinical needs in liver, uterine, and vascular care, introducing various products such as the proprietary multi-electrode Octopus system. The current rebranding signals a strategic commitment to expand beyond RFA by integrating diverse energy sources, including Microwave Ablation (MWA) and Irreversible Electroporation (IRE), into a unified therapeutic offering.

- Advertisement -

“With the global thermal ablation market projected to reach $2 billion by 2033, this rebranding is a pivotal step for our next stage of growth,” said CEO Henry Shin.

- Advertisement -

The newly unveiled Corporate Identity reflects both STARMED’s heritage and its future vision. The symbol represents technical precision by visualising the initial ‘S’ alongside the silhouette of an electrode tip. This reflects a dedication to minimising patient pain and providing care throughout the recovery process. The wordmark employs a sophisticated, futuristic typeface to reinforce trust within the global healthcare arena.

- Advertisement -

Supported by strong financial foundations, STARMED plans to capitalise on a market growing at 10.5% annually. The company remains committed to establishing minimally invasive treatments as the global ‘Standard of Care’ through enhanced clinical partnerships.

- Advertisement -

About STARMED

- Advertisement -

STARMED is a medical device specialist founded in 2009. With more than 660 clinical research evidence, the company provides world-class thermal ablation solutions to over 70 countries and continues to advance minimally invasive treatment as the clinical standard.

- Advertisement -

Photo – https://mma.prnewswire.com/media/2857156/STARMED_800px.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/starmed-unveils-new-brand-identity-to-drive-global-multi-modality-strategy-302655927.html

- Advertisement -

Recent Posts

Pictor Reports Strong Commercial Momentum One Year After Launching U.S. Headquarters

The targeted proteomic platform company marks its first anniversary in Carlsbad with four commercial partnerships,…

5 hours ago

LaennecAI launches Zorgm Pro: A free medical education answer engine built by doctors, for doctors

A clinician-only "ChatGPT for doctors" supporting continuing medical education, self-learning, and evidence-based clinical updating in…

5 hours ago

Fluent Inc. Subsidiary Trevant Launches as Creator Marketing Agency Built on Performance Discipline

Trevant pairs creator-native expertise with the measurement and scale infrastructure AdParlor spent a decade building…

8 hours ago

Scality and Biomemory partner to pioneer ultra-secure, DNA-based data archives with 150-year retention

SAN FRANCISCO and BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Scality, a global leader in…

8 hours ago

Rocket Doctor AI Announces Strong Q1 Momentum Driven by U.S. Expansion, New Payer Contracts and Platform Growth

Continued organic quarter over quarter revenue growth to $737KEarnings per share for Q1, 2026: ($0.05)…

8 hours ago

Philips announces exchange ratio for 2025 dividend

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that the exchange ratio for…

12 hours ago